Cold Spring Harbor Laboratory (CSHL) Associate Professor Pavel Osten and Professor Lloyd Trotman have developed a new way to study the life history of prostate cancer in mice. The pair combined their expertise in whole-organ ...
Nov 16, 2021
0
26
Regular blood tests before and during chemotherapy for prostate cancer can detect whether or not a patient is resistant or developing resistance to treatment with docetaxel, according to research presented at the NCRI Festival.
Nov 10, 2021
0
1
The immune checkpoint protein B7-H3 may be a promising new target for immunotherapy in treatment-resistant prostate cancers, according to two new studies led by researchers at the Johns Hopkins Kimmel Cancer Center. The studies ...
Nov 2, 2021
0
2
In a first-in-human, Phase I trial, researchers at The University of Texas MD Anderson Cancer Center discovered that ATR inhibitor RP-3500 was safe and well tolerated with promising clinical benefit. Principal investigator ...
Oct 8, 2021
0
29
Common gut bacteria can fuel the growth of prostate cancers and allow them to evade the effects of treatment, a new study finds.
Oct 7, 2021
0
133
Forget bedrest, research from Edith Cowan University (ECU) has shown exercise may be a key weapon in cancer patients' battle against the disease.
Oct 5, 2021
0
49
The international team led by Dr. Jacqui McGovern, from the Centre for Biomedical Technologies, used tissue engineering and regenerative medicine principles to create primary tumors with their microenvironment and humanized ...
Sep 28, 2021
0
46
When treating a cancer patient, oncologists aim to predict the course of the patient's disease to make critical treatment decisions. Knowing a tumor's unique molecular signature can help guide these decisions by providing ...
Sep 23, 2021
0
75
Research led by the Centenary Institute has found that a compound extracted from a commonly cultivated orchid could be a potential new treatment option for prostate cancer.
Sep 20, 2021
0
2
New findings by researchers at Yale Cancer Center show the drug combination of nivolumab and rucaparib shows clinical activity for patients with chemotherapy-naïve, metastatic castration resistant prostate cancer (mCRPC). ...
Sep 20, 2021
0
8
